TransdermIL Platform

Avro’s TransdermIL platform technology leverages the same ionic liquid formulations at the core of our TopicIL delivery technology to facilitate the systemic delivery of non-ideal small molecules and peptides, working on the same principles of lipid extraction, with a greater occlusive and concentrated thermodynamic driving force facilitating transdermal delivery.

Our ionic liquid formulations are combined with a uniquely amphiphilic and tunable polymer backbone, providing the structure and physical properties for the production of drug-in-adhesive patches imbued with the ILs’ permeation enhancing technologies.

Our internal pipeline focuses on transdermal formulations of therapeutics which we believe have the potential to become a standard of care, with an initial focus on injectable and infused therapies for neurological conditions, namely Parkinson’s Disease and ALS.


AVR101 is a once-a-day transdermal formulation of apomorphine for moderate-severe Parkinson’s disease, intended as an adjuvant therapy to levodopa/carbidopa, for the treatment of motor fluctuations in patients which are not sufficiently controlled by oral anti-Parkinsonian agents alone.

AVR101 is meant to serve as a replacement to more invasive methods of providing constant dopaminergic stimulation like pumps, multiple subcutaneous injections, and intestinal gels among others.


AVR201 is a once-a-day transdermal formulation of edaravone for symptomatic reduction of ALS. Edaravone is currently available only as a 14-day on/off daily IV infusion, and is the only drug on the market approved for treating the symptoms of ALS.

AVR201 is meant to improve ease of use and accessibility for patients suffering from ALS, allowing for at-home administration of the therapy, elimination of the need for a surgical port implant, and more flexible dosing options.

Our technology has drawn particular interest in the delivery of small molecules which cannot be formulated into oral dosage forms, and suffer from low bioavailability, low solubility, or other non-ideal pharmacokinetic profiles.

Ideal applications of our systemic delivery technology include:

Currently Parenteral Therapies
in elderly patients with motor or neurological conditions reducing ease of administration and compliance ie. Alzheimer’s Disease, Parkinson’s Disease, ALS, Duchenne Muscular Dystrophy, and more.
Emerging Modalities
currently only delivered as injections, ie. PROTACs / protein degraders
Controlled Release Therapeutics
which require a steady state or baseline conc. for ideal use ie. Certain antipsychotics, analgesics, anti-Parkinsonian agents, antibiotics, antivirals and more.
Low Solubility Topicals
which require localized delivery, free of systemic side effects, and suffer from low skin permeability and vehicle dissolution, ie. JAK inhibitors